期刊
CANCER TREATMENT REVIEWS
卷 66, 期 -, 页码 114-121出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2018.04.001
关键词
Locally advanced NSCLC; Radiochemotherapy; Consolidation therapy; Chemotherapy; Targeted therapy; Immunotherapy
类别
The majority of stage HI NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidation treatment has been put forward, whereby systemically active doses of chemotherapy, targeted therapy or immune therapy are administered after completion of radiochemotherapy. Randomized trials failed to provide support for consolidation chemotherapy or anti-EGFR therapies. Recently durvalumab, an anti-PD-L1 checkpoint inhibitor, administered as consolidation treatment, was shown to substantially improve progression-free survival. This article critically reviews major studies addressing the role of consolidation systemic therapies following definitive concurrent radiochemotherapy and discusses prospects for future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据